n/a
n/a
return equiti ttm
idc link barclay live interact chart
initi coverag overweight
initi coverag overweight
pt flawlessli execut drug develop cystic fibrosi cf build
franchis could address patient popul approv trikafta mark
begin end transform journey look well pois
short- long-term growth domin cf franchis cf far
biggest valu driver clinic program five differ indic beyond cf
includ antitrypsin defici aatd beta-thalassemia sickl cell
trikafta strong start expect rapid uptak beyond sinc approv
oct sale first launch alreadi reach includ
inventori base kol feedback expect rapid switch trikafta
exist therapi quick penetr previous unaddress treatment-
nave patient given well-docu genet profil patient trikafta
impress clinic profil expect trikafta provid strong top-line growth
project cf franchis reach peak potenti
opportun beyond cf cf journey continu search next
growth driver intern advanc program pain antitrypsin
defici aatd kidney diseas clinic extern
vrtx busi develop effort focus earli stage program
platform includ beta-thalassemia sickl cell diseas muscular dystrophi
type diabet start gener impress clinic proof-of-concept
signific cash accumul success cf franchis expect
opportunist activ busi develop activ continu
quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
launch trikafta beyond project
cf franchis reach peak potenti
beyond cf pipelin program beyond cf
aatd hemoglobinopathi could provid
robust project uptak trikafta
ou posit clinic data pipelin program
aatd
slower project uptak trikafta
slower expect market access progress ou
higher expect discontinu rate neg
clinic data pipelin program
risk rate price target
result preclin studi and/or earli stage studi serv basi
proof-of-concept efficaci safeti therapeut candid initi encourag
result respect activ safeti might translat success later-stag
even therapeut candid meet primari endpoint show clinic activ
guarante approv would issu regulatori agenc review process
regulatori agenc might take longer expect regulatori agenc might
request addit trial conduct actual approv
time could materi
drug launch might success due oper ineffici and/or competit
despit regulatori approv agreement compani partner might
chang
develop and/or
commerci drug candid market exclus
render patent
protection/extens statutori provis might end earlier expect
might impact drug sale price power innov drug might affect substanti
chang current reimburs framework took place
addit cash might need support develop clinic program
price target base sum-of-the-part probability-
valuat base probability-adjust dcf current asset includ
aatd assign technolog
platform acknowledg exact valuat technolog subject believ
addit valu vrtx technolog platform justifi given demonstr
capabl assign termin valu clinic asset use discount
rate believ appropri reflect risk asset
dcf valuationpres valu cash flow equival -net debt platform equiti valu equiti valu per dilut share dilut share discount valu barclay
pipelin catalyst
productdescriptionkalydecocftr potenti indic treatment cf patient age mon one mutat cftr gene respons ivacaf base clinic and/or vitro assay data includ mutat initi approv fda lumacaftor ivacaftor indic treatment cf patient y/o homozyg mutat initi approv fda jul tezacaftor ivacaftor indic treatment patient cf y/o homozyg mutat least one mutat cftr gene respons tezacaftor/ivacaftor base vitro data and/or clinic evid initi approv fda feb combin elexacaftor tezacaftor ivacaftor indic treatment cf patient y/o least one mutat cftr gene initi approv fda oct small molecul corrector z-aat initi small molecul corrector molecul inhibitor function causal genet factor fsgs/other proteinuri kidney diseas complet molecul inhibitor ex vivo gene edit collabor crsp profit share -cell-bas treatment deliveri system acquisit oct fibrosisaatdbt/scdtyp kidney approv age submiss potenti approv age proof-of-concept addit data proof-of-concept studi addit molecul clinic developmenttrikaftaaatdtyp fsgssymdeko/symkevibt/scdpain barclay
begin end cf journey
brief background cystic fibrosi
cystic fibrosi cf autosom recess monogenet rare diseas caus
mutat gene encod cystic fibrosi transmembran conduct regul
cftr result defect miss cftr protein apic anion channel respons
transport chlorid across cell membran mutat cftr
gene could lead impair chlorid ion transport cftr defici dysfunct
caus build-up mucu variou organ includ lung gastrointestin tract
pancrea organ pulmonari diseas respons vast major
morbid mortal patient cf mucu build airway lead
infect eventu progress lung damag
mutat cftr gene could categor five class base function
consequ figur class ii mutat common mutat
cf patient homozyg anoth compound
heterozygot mutat caus protein misfold degrad result
reduc number cftr channel cell membran cf common among
european descent peopl north america europ australia
estim cf includ
overview vrtx cftr franchis
prior treatment cf limit prevent manag diseas symptom
median age death around year old cystic fibrosi foundat patient registri
recent develop sever ground-break therapi remark clinic
effect address underli diseas vertex drug fall two categori
potenti ivacaftor extend open cftr channel therefor
improv chlorid ion flow corrector lumacaftor tezacaftor elexacaftor
help cftr protein traffick cell surfac correct fold defect
sinc initi approv kalydeco class gate mutat rel easi
address flawlessli execut drug develop addit difficult pt
popul receiv drug approv orkambi symdeko trikafta could
address cf pt popul mark begin end transform
classconsequenceexampl mutat cf pt least one mutat class pt least one mutat classapprov drugsclass function protein iicftr protein creat misfold keep move cell symdeko trikaftaclass iiicftr protein creat move cell surfac channel gate open ivcftr protein creat move cell surfac function channel symdekoclass vnormal cftr protein creat move cell surfac insuffici symdeko barclay
kalydeco potenti facilit chlorid transport improv
cftr channel open capabl initi approv patient year age
gate mutat jan sinc label expand includ
patient gate mutat well patient yr old
eventu mon old kalydeco monotherapi address cf patient
orkambi two-drug combin first-
gener corrector potenti patient homozyg mutat
impair cftr fold reduc number channel lumacaftor corrector
aid protein fold increas number cftr channel cell membran
orkambi initi approv patient year age homozyg
mutat label expand includ children age year old aug
orkambi dramat expand coverag
symdeko tezacaftor ivacaftor approv indic patient
homozyg one copi certain mutat result residu cftr
note comparison orkambi symdeko show slightli better efficaci
well improv safeti profil bronchoconstrict chest tight
trikafta elexacaftor tezacaftor ivacaftor tripl combin potenti ivacaftor
corrector tezacaftor next-gener corrector elexacaftor trikafta approv
oct patient year age least one mutat includ
homozygot trikafta approv expand address patient includ het-
min patient heterozyg minim function mutat expand
address popul vrtx cf franchis notabl efficaci
meaning improv trikafta provid improv treatment option major
patient current elig product approxim patient
current elig trikafta year old includ het-min patient
approv tripl combin europ patient year older well snda
submiss children age year expect
pt patient could eventu address vrtx current
cf franchis assum annual net treatment price base wac
price trikafta discontinu complianc estim
address market could
robust initi launch trikafta
trikafta approv fda octob five month ahead pdufa
date launch progress would play base sale
kol check believ trikafta could take major market share
trikafta launch exceed expect report trikafta sale vs
consensu exclud inventori stock sale still far
exceed expect guid revenu vs consensu
kol expect major patient swiftli switch trikafta kol
feedback consist strong launch trikafta-elig patient
het/min homozyg expect rapidli switch trikafta
reimburs note much issu treatment-nav
trikafta provid durabl cf franchis besid expand address market
switch elig patient trikafta would also increas patent life vrtx cf franchis
note eu countri expir eu countri expir eu countri
expir
cf franchis expect drive top-lin growth margin expans strong
revenu growth expect trikafta estim vrtx oper margin could
expand figur result earn growth signific cash
accumul would provid signific flexibl reinvest futur growth driver
growth oper leverag expect continu
cf diseas modifi therapi develop
drugstatu patentstatu eu patentkalydecogr margin companydrug specifiedcftr moleculecftr moleculeincreas reading-through prematur stop epitheli sodium channel enac encod fulli function cftr proeteini/iiinhaledptinesolicaftorsmal moleculecftr moleculecftr moleculecftr moleculenext-gener moleculedeuter ivacaftoriior barclay
search next cf stori
cf journey begin unwind search next growth driver
intern move program pain antitrypsin defici aatd
kidney diseas clinic extern vrtx busi develop
effort focus early-stag program platform includ beta-thalassemia
sickl cell diseas muscular dystrophi type diabet signific cash
accumul success cf franchis expect opportunist
activ busi develop activ
aatd autosom recess monogen diseas caus signific reduct
blood protein antitrypsin lead lung liver diseas encod
gene serin proteas inhibitor pi whose key function protect
lung proteolyt damag neutrophil elastas ne enzym releas
white blood cell respons infect green et al rev primer
primarili produc hepatocyt circul diffus
interstiti alveoli line inactiv ne common variant associ
sever defici aatd mutant caus singl amino acid substitut
residu mutat caus protein degrad
protein misfold protein fold correctli secret
circul loma chronic obstr pulm misfold protein accumul
endoplasm reticulum er hepatocyt lead liver fibrosi liver cirrhosi
moreov without suffici level keep elastas check alveoli lack anti-
proteas protect lead emphysema due loss elast structur integr
genet defici three common allel gene
normal allel allel defici gener associ
increas risk emphysema allel common pathogen
allel pi mm refer homozygos normal allel normal serum
level pi zz serum level normal figur
relationship variant serum level emphysema risk adult
aatd rel common under-diagnos rare diseas
peopl estim sever aatd due pi zz aboussouan stoller
respir howev aatd often underdiagnos reflect long
diagnost delay year symptomat onset green et al rev
primer diagnosi rate estim stoller ann thorac
current treatment option limit cur patient sever form
 pi zz level consid minimum protect
threshold abboud et al appl clin genet sever patient
emphysema approv treatment option augment therapi consist
intraven infus human plasma-deriv pd treatment
approv base circul level protect proteas
within lung wewer et al nejm due short half-lif pdaat
infus weekli maintain level treatment use slow
progress emphysema treatment ineffect liver manifest
diseas intrahepatocyt accumul due toxic gain-of-funct rather
diminish level specif treatment liver manifest
diseas sever liver diseas liver transplant may option
drug develop includ small molecul corrector misfold
protein rnai knockdown z- protein replac
aatd market product program clinic develop
propos approach aatd protein misfold diseas affect lung
among organ vrtx experi cf give advantag develop therapi
vertex develop oral small molecul corrector monotherapi could restor
level system address symptom lung well liver
preclin studi use transgen mous model carri human z-aat gene
treatment small molecul corrector result increas serum human
vs baselin protect threshold moreov treatment
result reduct polym format liver transgen mice
week treatment highlight potenti address patholog liver well
companydrug namemodalitymechanismphaseroagrifol prolastin-cproteinaugment therapyapprovedintravenouskmdaglassia iv proteinaugment therapyapprovedintravenousgrifol trypsoneproteinaugment therapyapprovedintravenouscsl ltdzemairaproteinaugment therapyapprovedintravenoustakedaaralastproteinaugment therapyapprovedintravenouskmda ih proteininh human hepatocyt mutant gene therapygen alvelestat small moleculeselect inhibitor human neutrophil moleculecorrector misfold moleculecorrector misfold hepatocyt mutant hepatocyt mutant moleculeselect inhibitor human neutrophil antibodyrecombin purifi human plasminogenproteinplasminogen replac barclay
rais circul level piz transgen mous
reduc toxic polym liver piz transgen mice
take portfolio approach aatd clinic trial decemb initi
studi evalu singl multipl dose healthi volunt base
safeti toler pk data initi dose-rang studi
studi evalu multipl dose vs placebo administ day
patient pi zz genotyp primari efficaci endpoint chang
level blood data studi expect similar portfolio approach
cf also initi studi anoth molecul
beta-thalassemia sickl cell diseas
well-understood genet valid clinic approach make beta-thalassemia
sickl cell diseas good target gene edit hemoglobin protein red blood
cell carri oxygen contain two alpha two beta chain adult two
alpha two gamma chain fetal beta-thalassemia bt sickl cell diseas
scd autosom recess blood disord result mutat beta-globin
bt patient variou specif mutat prevent normal product hemoglobin due
absenc reduc product beta-globin chain sever bt patient
scd patient singl point mutat result aggreg hemoglobin protein
hb low oxygen condit caus red blood cell sickl inflex
shape major clinic manifest scd hemolyt anemia intens pain
episod respiratori complic end-organ injuri earli mortal hobal et al
increas fetal hemoglobin could confer clinic benefit bt scd
chronic blood transfus common treatment hemoglobinopathi
allogeneic-hsct provid potenti cur therapeut path howev
treatment associ toxic fetal hemoglobin hbf greater affin
oxygen hbf nearli complet replac adult form mon age
increas product hbf function compens absenc beta-globin
chain hbf shown amelior bt scd symptom steinberg et al
blood clinic evid hbf benefit includ
express hbf shown reduc significantli clinic sever
scd patient et al hematol patient hbf
typic asymptomat despit exist hb
treatment hydroxyurea induc hbf scd patient could decreas
significantli acut symptom hbf level could boost maintain
explor induc product higher amount hbf either via induc
bianchi et al ecam gene therapy/gen edit approach goodman
gene therapi bt add function copi modifi form -globin gene a-
patient hematopoiet stem cell hsc use lentivir vector zynteglo
receiv condit approv eu jun base
studi show non- patient achiev transfus
independ median mon respect ex
vivo gene-edit cell therapi disrupt enhanc order upregul hbf
preliminari result three patient treat show less-than-optim hbf
level g/dl patient g/dl patient g/dl patient three
ex vivo crispr gene-edit therapi patient hsc
engin produc high level hbf red blood cell achiev disrupt
erythroid-specif enhanc gene use consequ
reduc express erythroid lineag cell would result upregul
gamma globin increas hbf level crsp form research
collabor discov develop gene edit approach address
genet diseas crsp receiv up-front payment potenti addit
mileston royalti payment result collabor vrtx/crsp co-
develop scd bt wherein profit would equal share
impress initi data bt/scd valid approach technolog crsp/vrtx
present promis initi result one sever bt patient
transfusion-independ g/dl total hb g/dl hbf
mon post-transfus one scd patient free vaso-occlus crise voc
g/dl total hb hbf f-cell erythrocyt express hbf
post-transfus safeti seem favor seriou advers event sae studi
deem relat although small number patient initi data
par better compar blue lentiglobin similar time point addit data
expect
hb level time bt patient treat
hb level time scd patient treat
clinic data summari gene therapy/edit beta-thalassemia
note biomark lenti-globin last visit defin ti weight averag hb g/dl without transfus month ortx defin ti hb g/dl adult g/dl
ped tdt transfus depend beta-thalassemia scd sickl cell diseas
compani present medic literatur barclay research estim
descriptionex-vivo lentivir gene therapi insert human -globin gene patient hscsex-vivo zfn editing/disrupt enhanc hsc produc fetal gamma-globinex-vivo crispr editing/disrupt enhanc hsc produc fetal gamma-globinstudi namenorthstar multicent ph single-cent global global multicent ph multicenterindicationtdttdt scdtdt sever scd s/ tdt adult adult adult pediatr adult adult age yr tdt pt scd datamanufacturingorigin processorigin processrefin processrefin processlymphodeplet busulfan condit mg/kg initi adjust base first dose pk busulfan condit mg/kg initi adjust base daili pk busulfan condit daili average estim auc min busulfan condit daili average estim auc min tiotepa treosulfan conditioningbusulfan conditioningbusulfan conditioningian drug product vector copi number vcn cell transduc peripher vcn monmonth monian hbf g/dl mon pt g/dl wk g/dl wk g/dl day level reach g/dl mon peripher f-cell circul rbc express hbf ian total hb g/dl mon pt ti patient ped hb level g/dl monpati achiev transfus independ patientstdt evalu patient achiev ti patient mon follow-up transfusion-fre pediatr patient becam ti adult reduc transfus requirementpt resum transfus week transfusion-fre pt intermitt transfus pt resum transfus week transfusion-freeian durat ti patient mon patient mon tdt patient mon mon ti patient mon patient ped mon mon ian weight average hb g/dl ti tdt ti patient g/dl g/dl last ti patient ped jun et al nejm posterthompson et al nejm abstract poster poster presentationmerktel et al asgct presentationsgmo present abstractcrsp present ex-vivo lentivir gene therapi insert hba patient hematopoeit stem cell hsc barclay
clinic data summari gene therapy/edit sickl cell diseas
note biomark lenti-globin last visit defin ti weight averag hb g/dl without transfus
month ortx defin ti hb g/dl adult g/dl ped tdt transfus depend beta-thalassemia scd sickl cell diseas
compani present medic literatur barclay research estim
descriptionex-vivo lentivir gene therapi insert shrna patient hsc knockdown enhanc ex-vivo crispr editing/disrupt enhanc hsc produc fetal gamma-globinstudi group origin process group improv group refin process nct descriptionph single-cent ph open label multicenterph open label multicenterph singl centerph single-arm multicenterindicationtdt scdsever scdsever scdsever scdsever scd scd s/ tdt group s/ group s/ group scd patient s/ scd s/smedian age yr tdt pt scd ptsgroup datamanufacturingorigin processgroup origin processgroup improv processrefin processlymphodeplet regimenbusulfan conditioningbusulfan conditioningbusulfan conditioningbusulfan conditioningbusulfan conditioningmedian drug product vector copi number vcn rang scd cell transduc rang group peripher vcn rang patient mongroup mongroup month month month month hbf g/dl last visitscd mongroup last visitgroup last monmedian total hb g/dl rang scd mongroup mongroup monperipher f-cell circul rbc express month month month month month monmedian anti-sickl hb total hb rang pt mon pt mon pt mon group mon group month month month month month mon reduct rang median annual rate vaso-occlus crisi voc plu acut chest syndrom patient voc ac mon pt mon f/u median annual voc post-treat vs pretreat voe pain gene therapi respiratori neurolog event transfus except pre-exist patient report voc sinc infusiondata jun abstract posterash abstract posterash abstract posterash abstract posternov crsp presentationbluelentiglobinex-vivo lentivir gene therapi insert hba patient hematopoeit stem cell hsc barclay
clinic program fsg
inherit mutat gene causal genet factor proteinur kidney
diseas includ focal segment glomerulosclerosi fsg fsg rare renal
diseas character proteinuria leakag protein urin follow progress
scar glomeruli eventu lead end-stag renal diseas fsg lead caus
nephrot syndrom children kidney failur adult among african american
descent two common genet variant apolipoprotein gene
variant associ fsg dummer et al semin nephrol
follow autosom recess pattern management estim patient
fsg homozyg mutat
oral small molecul inhibitor function sad/mad studi
evalu health volunt initi june complet late
open-label proof-of-concept dose-rang studi expect initi
evalu abil reduc proteinuria fsg similar small molecul
pipelin program advanc multipl addit molecul
